Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

meayamycin B

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Meayamycin B is currently the most potent modulator of the splicing factor 3b subunit 1 and used by dozens of research groups… Expand
2019
2019
Introduction Therapeutic options for diffuse malignant peritoneal mesothelioma (DMPM) are limited to surgery and locoregional… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
Adeno-associated viruses (AAV) have evolved to exploit the dynamic reorganization of host cell machinery during co-infection by… Expand
2014
2014
ABT-737 inhibits the anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and BCL-XL. Meayamycin B switches the splicing pattern of… Expand
  • figure 1
  • figure 2
  • figure 4
2014
2014
Introduction The process of pre-mRNA splicing is gaining attention as a contributor to anticancer drug resistance and as a… Expand
2014
2014
ABT-737 inhibits the anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and BCL-XL. Meayamycin B switches the splicing pattern of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2013
Highly Cited
2013
The myeloid cell leukemia-1 (MCL1) gene encodes antiapoptotic Mcl-1(L) and proapoptotic Mcl-1(S) proteins. In cancer, the Mcl-1(L… Expand
2013
2013
This study explored the application of the alternative splicing of Bcl-2 family protein Mcl-1 in combination chemotherapy for… Expand